Search

Your search keyword '"Xie, Qiufen"' showing total 185 results
Start Over Author "Xie, Qiufen"
185 results on '"Xie, Qiufen"'

17. Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers

Author

Mu, Guangyan, Xie, Qiufen, Liu, Zhiyan, Zhang, Hanxu, Meng, Xianmin, Song, Jinfang, Zhou, Shuang, Wang, Zhe, Wang, Zining, Zhao, Xia, Jiang, Jie, Liao, Maoxing, Bao, Jiachun, Zhang, Fan, Xiang, Qian, and Cui, Yimin

Subjects
Pharmacology, General Medicine, Toxicology
Abstract

Apixaban is a superior direct oral anticoagulant exihibiting interindividual variability in concentration and response in the real world. The present study aimed to identify genetic biomarkers associated with pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban in healthy Chinese subjects. This multicenter study included 181 healthy Chinese adults taking a single dose of 2.5 mg or 5 mg apixaban and assessed their PK and PD parameters. Genome-wide single nucleotide polymorphism (SNP) genotyping was performed using the Affymetrix Axiom CBC_PMRA Array. Candidate gene association analysis and genome-wide association study were conducted to identify genes with a predictive value for PK and PD parameters of apixaban. Several ABCG2 variants were associated with Cmax and AUC0-t of apixaban (p < 6.12 × 10−5) and also presented significant differences of anti-Xa3h activity and dPT3h according to different ABCG2 genotypes (p < 0.05). Besides, ABLIM2 variants were found to be associated with PK characteristics and F13A1 and C3 variants were associated with PD characteristics of apixaban (p < 9.46 × 10−8). ABCG2 variants were found to be ideal genetic biomarkers for both PK and PD characteristics of apixaban. ABLIM2, F13A1 and C3 were identified as potential candidate genes associated with inter-individual variability of apixaban. This study was registered on ClinicalTrials.gov NCT03259399.

Published
2023

18. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study

Author

Xiang, Qian, primary, Wang, Zhe, additional, Mu, Guangyan, additional, Xie, Qiufen, additional, Liu, Zhiyan, additional, Zhou, Shuang, additional, Zhang, Hanxu, additional, Wang, Zining, additional, Jiang, Jie, additional, Hu, Kun, additional, Zhang, Yatong, additional, Zhao, Zinan, additional, Yuan, Dongdong, additional, Guo, Liping, additional, Wu, Tingting, additional, Zhang, Jinhua, additional, Wang, Na, additional, Xiang, Jing, additional, Gu, Zhichun, additional, Sun, Jianjun, additional, and Cui, Yimin, additional

Published
2023
Full Text
View/download PDF

22. Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study

Author

Xiang, Qian, primary, Xie, Qiufen, additional, Liu, Zhiyan, additional, Mu, Guangyan, additional, Zhang, Hanxu, additional, Zhou, Shuang, additional, Wang, Zhe, additional, Wang, Zining, additional, Zhang, Yatong, additional, Zhao, Zinan, additional, Yuan, Dongdong, additional, Guo, Liping, additional, Wang, Na, additional, Xiang, Jing, additional, Song, Hongtao, additional, Sun, Jianjun, additional, Jiang, Jie, additional, and Cui, Yimin, additional

Published
2022
Full Text
View/download PDF

23. PROK2 , HRNR , and FIG4 as potential genetic biomarkers of high bleeding propensity in East Asian patients with acute coronary syndrome using ticagrelor

Author

Xiang, Qian, primary, Wang, Zhe, additional, Mu, Guangyan, additional, Xie, Qiufen, additional, Liu, Zhiyan, additional, Zhou, Shuang, additional, Zhang, Hanxu, additional, Wang, Zining, additional, Hu, Kun, additional, Song, Hongtao, additional, Yuan, Dongdong, additional, Xia, Quan, additional, Huang, Yan, additional, and Cui, Yimin, additional

Published
2022
Full Text
View/download PDF

26. Additional file 4 of Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban

Author

Zhang, Hanxu, Zhang, Zhuo, Liu, Zhiyan, Mu, Guangyan, Xie, Qiufen, Zhou, Shuang, Wang, Zhe, Cao, Yu, Tan, Yunlong, Wei, Xiaohua, Yuan, Dongdong, Xiang, Qian, and Cui, Yimin

Abstract

Additional file 4. Table S4: Risk estimates of 3 h miRNA levels for rivaroxaban response by univariate logistic analysis in healthy volunteers

Published
2023
Full Text
View/download PDF

28. Additional file 2 of Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban

Author

Zhang, Hanxu, Zhang, Zhuo, Liu, Zhiyan, Mu, Guangyan, Xie, Qiufen, Zhou, Shuang, Wang, Zhe, Cao, Yu, Tan, Yunlong, Wei, Xiaohua, Yuan, Dongdong, Xiang, Qian, and Cui, Yimin

Abstract

Additional file 2. Table S2: Analytics for the assessment of rivaroxaban plasma concentrations in healthy volunteers in sub-centers

Published
2023
Full Text
View/download PDF

30. Additional file 3 of Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban

Author

Zhang, Hanxu, Zhang, Zhuo, Liu, Zhiyan, Mu, Guangyan, Xie, Qiufen, Zhou, Shuang, Wang, Zhe, Cao, Yu, Tan, Yunlong, Wei, Xiaohua, Yuan, Dongdong, Xiang, Qian, and Cui, Yimin

Abstract

Additional file 3. Table S3: Comparison of plasma miR-320a and miR-483 levels between the case and control groups in healthy volunteers

Published
2023
Full Text
View/download PDF

31. Additional file 6 of Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban

Author

Zhang, Hanxu, Zhang, Zhuo, Liu, Zhiyan, Mu, Guangyan, Xie, Qiufen, Zhou, Shuang, Wang, Zhe, Cao, Yu, Tan, Yunlong, Wei, Xiaohua, Yuan, Dongdong, Xiang, Qian, and Cui, Yimin

Abstract

Additional file 6. Table S6: Risk estimates of 3 h miRNA levels for rivaroxaban response by univariate logistic analysis in patients

Published
2023
Full Text
View/download PDF

39. Additional file 2 of Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis

Author

Xie, Qiufen, Xiang, Qian, Liu, Zhiyan, Mu, Guangyan, Zhou, Shuang, Zhang, Zhuo, Ma, Lingyue, Gong, Yanjun, Jiang, Jie, and Cui, Yimin

Abstract

Additional file 2. The quality of the included studies assessed using the Newcastle���Ottawa Scale.

Published
2022
Full Text
View/download PDF

46. Anti-FXa-IIa activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study

Author

Liu, Zhiyan, primary, Xie, Qiufen, additional, Xiang, Qian, additional, Zhang, Hanxu, additional, Mu, Guangyan, additional, Zhao, Zinan, additional, Hu, Taotao, additional, Wu, Tingting, additional, Wang, Na, additional, Zhang, Jinhua, additional, Qian, Yan, additional, Zhou, Shuang, additional, Wang, Zining, additional, Jiang, Jie, additional, Zhang, Yatong, additional, Song, Hongtao, additional, and Cui, Yimin, additional

Published
2020
Full Text
View/download PDF

47. PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case–control genome-wide study

Author

Mu, Guangyan, primary, Xiang, Qian, additional, Zhang, Zhuo, additional, Liu, Chengzhang, additional, Zhang, Hanxu, additional, Liu, Zhiyan, additional, Pang, Xiaocong, additional, Jiang, Jie, additional, Xie, Qiufen, additional, Zhou, Shuang, additional, Wang, Zining, additional, Hu, Kun, additional, Wang, Zhe, additional, Jiang, Shanqun, additional, Qin, Xianhui, additional, and Cui, Yimin, additional

Published
2020
Full Text
View/download PDF

50. Genotype‐guided antiplatelet treatment versus conventional therapy: A systematic review and meta‐analysis.

Author

Zhang, Hanxu, Xiang, Qian, Liu, Zhiyan, Mu, Guangyan, Xie, Qiufen, Zhou, Shuang, Ma, Lingyue, Wang, Zining, Hu, Kun, Wang, Zhe, and Cui, Yimin

Subjects
DRUG-eluting stents, META-analysis, PERCUTANEOUS coronary intervention, MYOCARDIAL infarction, CARDIOVASCULAR diseases, CORONARY disease
Abstract

Aim: This meta‐analysis was carried out to explore if a personalized antiplatelet strategy based on genotyping is superior to conventional therapy. Methods: PubMed, Web of Science, EMBASE and the Cochrane Library were searched from the inception of each database to 5 May 2020. Studies reporting endpoints in genotype‐guided treatment group and conventional treatment group were included. The endpoint results were presented as the risk ratio (RR), with 95% confidence interval (CI). Results: A total of 10 561 patients from 16 studies (eight randomized controlled trials [RCT] and eight cohort studies) were included in the meta‐analysis. The rates of major adverse cardiovascular events (MACE), stent thrombosis and myocardial infarction (MI) were significantly lower in the genotype‐guided group than in the conventional treatment group (RR 0.56, 95% CI 0.44‐0.73, P <.0001; RR 0.40, 95% CI 0.24‐0.67, P =.0005; RR 0.45, 95% CI 0.35‐0.58, P <.00001, respectively). A significant difference was found between the two groups in major bleeding (RR 0.73, 95% CI 0.55‐0.98, P =.04), which was not robust after sensitivity analysis. Conclusion: Genotype‐guided antiplatelet treatment could decrease the risk of MACE, stent thrombosis and MI in patients with coronary artery disease or undergoing percutaneous coronary intervention, without increasing the risk of bleeding over a long follow‐up period. The decreased risk of efficacy outcomes was more obvious in cohort studies. Well‐organized RCTs and clinical trials are required to verify the benefit of genotype‐guided therapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results